Blood Gene Expression Profiling in Liver Transplant Recipients With Hepatitis C Virus and Posttransplantation Diabetes Mellitus

C. J. Driscoll, A. K. Cashion, Donna Hathaway, C. Thompson, Y. Conley, C. Riely, L. Xu, R. Homayouni

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Hepatitis C virus (HCV) is a risk factor for developing posttransplantation diabetes mellitus (PTDM) after liver transplantation; little is known about the biological mechanisms involved with this risk. This study investigated gene expression differences to provide insight into potential mechanisms. Patients and Methods: Gene expression profiles of blood samples obtained from 6 HCV+ liver transplant recipients were determined using Affymetrix U133 Plus 2.0 microarrays. Differential gene expression was assessed between HCV+ recipients with PTDM (n = 3) and without PTDM (n = 3) using the GeneSpring 7.3 software package. The Welch t test was used to identify significant differences (P < .05) between groups. Gene expression profiles for 6 HCV- liver transplant recipients (with PTDM = 3, without PTDM = 3) were used as a blind test set to evaluate a subset of genes to predict PTDM. Results: Expression levels of 347 genes were significantly different between recipients with PTDM and those without PTDM. Seventy-four genes were up-regulated and 270 were down-regulated in PTDM. Genes were categorized into functional classes: apoptosis (n = 69 genes); immune function (n = 110); diabetes (n = 17); hepatitis C (n = 12); liver transplant (n = 69). The expression profile of a subset of genes was evaluated for predicting PTDM in 6 HCV- transplant recipients. We accurately predicted the presence or absence of PTDM in 5/6 recipients. Conclusions: PTDM in HCV+ liver transplant recipients was associated with down-regulated expression of a large number of genes. A subset of these genes was useful to predict PTDM in HCV- recipients. Most genes were associated with apoptosis and immune function. HCV may act as a primer by affecting a group of genes involved in developing diabetes.

Original languageEnglish (US)
Pages (from-to)3646-3648
Number of pages3
JournalTransplantation Proceedings
Volume38
Issue number10
DOIs
StatePublished - Dec 1 2006

Fingerprint

Gene Expression Profiling
Hepacivirus
Diabetes Mellitus
Liver
Genes
Transcriptome
Transplant Recipients
Apoptosis
Gene Expression
Hepatitis C
Liver Transplantation
Software
Transplants

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

Blood Gene Expression Profiling in Liver Transplant Recipients With Hepatitis C Virus and Posttransplantation Diabetes Mellitus. / Driscoll, C. J.; Cashion, A. K.; Hathaway, Donna; Thompson, C.; Conley, Y.; Riely, C.; Xu, L.; Homayouni, R.

In: Transplantation Proceedings, Vol. 38, No. 10, 01.12.2006, p. 3646-3648.

Research output: Contribution to journalArticle

Driscoll, C. J. ; Cashion, A. K. ; Hathaway, Donna ; Thompson, C. ; Conley, Y. ; Riely, C. ; Xu, L. ; Homayouni, R. / Blood Gene Expression Profiling in Liver Transplant Recipients With Hepatitis C Virus and Posttransplantation Diabetes Mellitus. In: Transplantation Proceedings. 2006 ; Vol. 38, No. 10. pp. 3646-3648.
@article{7cd73552d95d454389cf2f8941ceb473,
title = "Blood Gene Expression Profiling in Liver Transplant Recipients With Hepatitis C Virus and Posttransplantation Diabetes Mellitus",
abstract = "Background: Hepatitis C virus (HCV) is a risk factor for developing posttransplantation diabetes mellitus (PTDM) after liver transplantation; little is known about the biological mechanisms involved with this risk. This study investigated gene expression differences to provide insight into potential mechanisms. Patients and Methods: Gene expression profiles of blood samples obtained from 6 HCV+ liver transplant recipients were determined using Affymetrix U133 Plus 2.0 microarrays. Differential gene expression was assessed between HCV+ recipients with PTDM (n = 3) and without PTDM (n = 3) using the GeneSpring 7.3 software package. The Welch t test was used to identify significant differences (P < .05) between groups. Gene expression profiles for 6 HCV- liver transplant recipients (with PTDM = 3, without PTDM = 3) were used as a blind test set to evaluate a subset of genes to predict PTDM. Results: Expression levels of 347 genes were significantly different between recipients with PTDM and those without PTDM. Seventy-four genes were up-regulated and 270 were down-regulated in PTDM. Genes were categorized into functional classes: apoptosis (n = 69 genes); immune function (n = 110); diabetes (n = 17); hepatitis C (n = 12); liver transplant (n = 69). The expression profile of a subset of genes was evaluated for predicting PTDM in 6 HCV- transplant recipients. We accurately predicted the presence or absence of PTDM in 5/6 recipients. Conclusions: PTDM in HCV+ liver transplant recipients was associated with down-regulated expression of a large number of genes. A subset of these genes was useful to predict PTDM in HCV- recipients. Most genes were associated with apoptosis and immune function. HCV may act as a primer by affecting a group of genes involved in developing diabetes.",
author = "Driscoll, {C. J.} and Cashion, {A. K.} and Donna Hathaway and C. Thompson and Y. Conley and C. Riely and L. Xu and R. Homayouni",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/j.transproceed.2006.10.116",
language = "English (US)",
volume = "38",
pages = "3646--3648",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Blood Gene Expression Profiling in Liver Transplant Recipients With Hepatitis C Virus and Posttransplantation Diabetes Mellitus

AU - Driscoll, C. J.

AU - Cashion, A. K.

AU - Hathaway, Donna

AU - Thompson, C.

AU - Conley, Y.

AU - Riely, C.

AU - Xu, L.

AU - Homayouni, R.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Background: Hepatitis C virus (HCV) is a risk factor for developing posttransplantation diabetes mellitus (PTDM) after liver transplantation; little is known about the biological mechanisms involved with this risk. This study investigated gene expression differences to provide insight into potential mechanisms. Patients and Methods: Gene expression profiles of blood samples obtained from 6 HCV+ liver transplant recipients were determined using Affymetrix U133 Plus 2.0 microarrays. Differential gene expression was assessed between HCV+ recipients with PTDM (n = 3) and without PTDM (n = 3) using the GeneSpring 7.3 software package. The Welch t test was used to identify significant differences (P < .05) between groups. Gene expression profiles for 6 HCV- liver transplant recipients (with PTDM = 3, without PTDM = 3) were used as a blind test set to evaluate a subset of genes to predict PTDM. Results: Expression levels of 347 genes were significantly different between recipients with PTDM and those without PTDM. Seventy-four genes were up-regulated and 270 were down-regulated in PTDM. Genes were categorized into functional classes: apoptosis (n = 69 genes); immune function (n = 110); diabetes (n = 17); hepatitis C (n = 12); liver transplant (n = 69). The expression profile of a subset of genes was evaluated for predicting PTDM in 6 HCV- transplant recipients. We accurately predicted the presence or absence of PTDM in 5/6 recipients. Conclusions: PTDM in HCV+ liver transplant recipients was associated with down-regulated expression of a large number of genes. A subset of these genes was useful to predict PTDM in HCV- recipients. Most genes were associated with apoptosis and immune function. HCV may act as a primer by affecting a group of genes involved in developing diabetes.

AB - Background: Hepatitis C virus (HCV) is a risk factor for developing posttransplantation diabetes mellitus (PTDM) after liver transplantation; little is known about the biological mechanisms involved with this risk. This study investigated gene expression differences to provide insight into potential mechanisms. Patients and Methods: Gene expression profiles of blood samples obtained from 6 HCV+ liver transplant recipients were determined using Affymetrix U133 Plus 2.0 microarrays. Differential gene expression was assessed between HCV+ recipients with PTDM (n = 3) and without PTDM (n = 3) using the GeneSpring 7.3 software package. The Welch t test was used to identify significant differences (P < .05) between groups. Gene expression profiles for 6 HCV- liver transplant recipients (with PTDM = 3, without PTDM = 3) were used as a blind test set to evaluate a subset of genes to predict PTDM. Results: Expression levels of 347 genes were significantly different between recipients with PTDM and those without PTDM. Seventy-four genes were up-regulated and 270 were down-regulated in PTDM. Genes were categorized into functional classes: apoptosis (n = 69 genes); immune function (n = 110); diabetes (n = 17); hepatitis C (n = 12); liver transplant (n = 69). The expression profile of a subset of genes was evaluated for predicting PTDM in 6 HCV- transplant recipients. We accurately predicted the presence or absence of PTDM in 5/6 recipients. Conclusions: PTDM in HCV+ liver transplant recipients was associated with down-regulated expression of a large number of genes. A subset of these genes was useful to predict PTDM in HCV- recipients. Most genes were associated with apoptosis and immune function. HCV may act as a primer by affecting a group of genes involved in developing diabetes.

UR - http://www.scopus.com/inward/record.url?scp=33845468279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845468279&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2006.10.116

DO - 10.1016/j.transproceed.2006.10.116

M3 - Article

VL - 38

SP - 3646

EP - 3648

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -